drugset
drugset / Trial / NCT05664542

Erector Spinae Block With Ropivacaine and Dexmedetomidine on Opioid Consumption After Lumar Spine Surgeries

NCT05664542 ↗

Phase 4 Unknown 42 enrolled Security Forces Hospital
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The aim of this study is to investigate the role of 0.5 micrograms/kg of dexmedetomidine with 0.2 % ropivacaine in erector spinae block in reducing opioid consumption for patients undergoing lumbar spine surgeries. This study will help in understanding the role of adding dexmdetomidine to ropivacaine in erector spinae block in reducing opioid consumption after lumbar spine surgeries

Timeline

Start
2022-12-15
Primary completion
2023-04-30
Completion
2023-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 0.5 ug/kg —
Subject Ropivacaine Other / unclassified 0.2 % —

Indications

No indication recorded.